Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTNM Contineum Therapeutics	$6.75 +5.0%	$4.76	$3.35 ▼ $20.55	$166.35M	1.04	323,599 shs	82,537 shs
KROS Keros Therapeutics	$13.71 +2.7%	$13.98	$9.12 ▼ $72.37	$542.22M	1.33	447,641 shs	305,989 shs
PHAT Phathom Pharmaceuticals	$10.38 +1.0%	$9.04	$2.21 ▼ $19.71	$729.30M	0.45	1.10 million shs	1.04 million shs
TSHA Taysha Gene Therapies	$2.91 +5.4%	$2.59	$1.05 ▼ $3.31	$592.47M	0.98	2.56 million shs	4.90 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTNM Contineum Therapeutics	-0.62%	+10.86%	+64.03%	+68.77%	-60.58%
KROS Keros Therapeutics	-2.77%	-8.69%	-7.55%	-0.89%	-70.58%
PHAT Phathom Pharmaceuticals	+5.54%	+18.98%	+11.98%	+210.57%	-12.51%
TSHA Taysha Gene Therapies	+1.47%	+1.85%	+4.55%	+17.95%	+32.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTNM Contineum Therapeutics	3.0885 of 5 stars	3.6	3.0	3.1	0.8	1.3
KROS Keros Therapeutics	2.6622 of 5 stars	3.3	2.0	2.2	3.3	0.6
PHAT Phathom Pharmaceuticals	3.1505 of 5 stars	3.5	2.0	1.6	5.0	0.6
TSHA Taysha Gene Therapies	2.994 of 5 stars	4.5	0.0	3.0	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTNM Contineum Therapeutics	3.17	Buy	$22.50	233.33% Upside
KROS Keros Therapeutics	2.50	Moderate Buy	$30.00	118.82% Upside
PHAT Phathom Pharmaceuticals	3.00	Buy	$17.50	68.59% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$8.33	186.37% Upside

Current Analyst Ratings Breakdown

Latest CTNM, PHAT, KROS, and TSHA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	TSHA Taysha Gene Therapies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
8/8/2025	KROS Keros Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $20.00
7/11/2025	TSHA Taysha Gene Therapies	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
7/1/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/20/2025	CTNM Contineum Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/10/2025	KROS Keros Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$32.00 ➝ $18.00
6/10/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/9/2025	PHAT Phathom Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $17.00
6/9/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00
6/3/2025	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $11.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTNM Contineum Therapeutics	$50M	3.49	N/A	N/A	$6.62 per share	1.02
KROS Keros Therapeutics	$3.55M	156.87	N/A	N/A	$17.40 per share	0.79
PHAT Phathom Pharmaceuticals	$55.25M	13.33	N/A	N/A	($5.72) per share	-1.81
TSHA Taysha Gene Therapies	$8.33M	74.99	N/A	N/A	$0.35 per share	8.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTNM Contineum Therapeutics	-$42.26M	-$2.20	N/A	N/A	N/A	N/A	-29.75%	-28.08%	8/12/2025 (Estimated)
KROS Keros Therapeutics	-$187.35M	$0.31	44.23	N/A	1.19	8.06%	2.96%	2.74%	N/A
PHAT Phathom Pharmaceuticals	-$334.33M	-$4.73	N/A	N/A	N/A	-289.51%	N/A	-90.40%	N/A
TSHA Taysha Gene Therapies	-$89.30M	-$0.34	N/A	N/A	N/A	-1,201.08%	-104.93%	-50.09%	8/12/2025 (Estimated)

Latest CTNM, PHAT, KROS, and TSHA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	TSHA Taysha Gene Therapies	-$0.07	-$0.09	-$0.02	-$0.09	$1.61 million	$1.99 million
8/6/2025	Q2 2025	KROS Keros Therapeutics	-$1.14	-$0.76	+$0.38	-$0.76	$3.83 million	$0.02 million
8/5/2025	Q2 2025	CTNM Contineum Therapeutics	-$0.56	-$0.62	-$0.06	-$0.62	$7.50 million	N/A
5/15/2025	Q1 2025	TSHA Taysha Gene Therapies	-$0.08	-$0.08	N/A	-$0.08	$1.48 million	$2.30 million
5/14/2025	Q1 2025	CTNM Contineum Therapeutics	-$0.56	-$0.62	-$0.06	-$0.62	$7.50 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
KROS Keros Therapeutics	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTNM Contineum Therapeutics	N/A	24.51	24.51
KROS Keros Therapeutics	N/A	21.11	21.11
PHAT Phathom Pharmaceuticals	N/A	2.38	2.35
TSHA Taysha Gene Therapies	0.77	5.35	5.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTNM Contineum Therapeutics	N/A
KROS Keros Therapeutics	71.56%
PHAT Phathom Pharmaceuticals	99.01%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
CTNM Contineum Therapeutics	11.30%
KROS Keros Therapeutics	22.90%
PHAT Phathom Pharmaceuticals	24.10%
TSHA Taysha Gene Therapies	3.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTNM Contineum Therapeutics	31	25.87 million	22.95 million	N/A
KROS Keros Therapeutics	100	40.62 million	31.31 million	Optionable
PHAT Phathom Pharmaceuticals	110	70.94 million	53.85 million	Optionable
TSHA Taysha Gene Therapies	180	214.66 million	206.55 million	Optionable

CTNM, PHAT, KROS, and TSHA Headlines

Recent News About These Companies

Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates

August 12 at 4:01 PM | zacks.com

Taysha Gene Therapies, Inc. (TSHA) Q2 2025 Earnings Call Transcript

August 12 at 2:06 PM | seekingalpha.com

Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 12 at 8:01 AM | globenewswire.com

Analysts Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Target Price at $8.17

August 11 at 2:17 AM | americanbankingnews.com

Taysha Gene Therapies (TSHA) Projected to Post Earnings on Tuesday

August 11 at 2:33 AM | americanbankingnews.com

Jefferies Financial Group Inc. Invests $341,000 in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

August 9 at 3:59 AM | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Recommendation of "Buy" by Brokerages

August 9 at 3:22 AM | marketbeat.com

Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12

August 5, 2025 | globenewswire.com

Taysha Gene Therapies (TSHA) Expected to Announce Earnings on Monday

August 5, 2025 | marketbeat.com

Wells Fargo Remains Bullish on Taysha Gene Therapies (TSHA)

August 5, 2025 | msn.com

Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know

August 4, 2025 | zacks.com

BIT Capital GmbH Purchases New Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

August 4, 2025 | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Short Interest Update

August 2, 2025 | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Sees Large Increase in Short Interest

August 2, 2025 | americanbankingnews.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 1, 2025 | globenewswire.com

Needham Maintains a Buy on Taysha Gene Therapies (TSHA), Keeps PT at $8

August 1, 2025 | msn.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading 8.6% Higher - Should You Buy?

July 31, 2025 | marketbeat.com

Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade

July 16, 2025 | zacks.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.7% - Here's Why

July 15, 2025 | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Rating of "Buy" from Analysts

July 14, 2025 | marketbeat.com

B of A Securities Initiates Coverage of Taysha Gene Therapies (TSHA) with Buy Recommendation

July 12, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM, PHAT, KROS, and TSHA Company Descriptions

Contineum Therapeutics NASDAQ:CTNM

$6.75 +0.32 (+4.98%)

Closing price 04:00 PM Eastern

Extended Trading

$6.68 -0.07 (-1.04%)

As of 06:25 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Keros Therapeutics NASDAQ:KROS

$13.71 +0.36 (+2.70%)

Closing price 04:00 PM Eastern

Extended Trading

$13.70 -0.01 (-0.04%)

As of 04:31 PM Eastern

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Phathom Pharmaceuticals NASDAQ:PHAT

$10.38 +0.10 (+0.97%)

Closing price 04:00 PM Eastern

Extended Trading

$10.31 -0.07 (-0.67%)

As of 06:58 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Taysha Gene Therapies NASDAQ:TSHA

$2.91 +0.15 (+5.43%)

Closing price 04:00 PM Eastern

Extended Trading

$2.88 -0.03 (-1.03%)

As of 07:20 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time